Influence of intraoperative use of remifentanil to postpoerative nausea and vomiting(PONV)

Influence of intraoperative use of remifentanil to postpoerative nausea and vomiting(PONV) - Influence of intraoperative use of remifentanilto PONV

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000016110

Enrollment

150

Registered

2015-01-05

Start date

2015-01-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

upper extremity surgery

Interventions

The intraoperative use of remifentanil The intraoperative nonuse of remifentanil

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with ASA-PS 1-3 Patients who consent

Exclusion criteria

Exclusion criteria: Patients who did not consent Patients with allergy of local anesthetics Pregnant or lactating women Patients with liver failure or renal failure Patients with bradycardia(HR<40bpm)

Design outcomes

Primary

Measure	Time frame
The incidence of postoperative nausea	—

Secondary

Measure	Time frame
Respiratory rate at the time of leaving Time until spontaneous breathing appear Total dose of remifentanil End-tidal sevoflurane concentration at the time of awakening NRS at rest	—

Countries

Japan

Contacts

Public ContactTatsunori Wataanbe

Niigata University Medical and Dental Hospital Department of Anestesio;ogy

deepimpact034@yahoo.co.jp025-227-2328

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026